Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide in Latino adults with type 2 diabetes
NCT04938388Phase 4Terminated
- Sponsor
- Sansum Diabetes Research Institute
- Start
- Jan 2022
- Primary completion
- Feb 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial in type 2 diabetes mellitus (T2DM) comparing Oral Semaglutide + Vegetables with Placebo + Vegetables (2 arms). Primary endpoint: Percentage of participants achieving HbA1c less than 7.0% at 50 weeks. Started Jan 2022; status: terminated.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04938388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04938388.